

# John T Lear

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3817722/publications.pdf>

Version: 2024-02-01

59  
papers

3,043  
citations

218592

26  
h-index

161767

54  
g-index

60  
all docs

60  
docs citations

60  
times ranked

3345  
citing authors

#	ARTICLE	IF	CITATIONS
1	Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments). British Journal of Dermatology, 2022, 187, 324-337.	1.4	15
2	Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months. Journal of the American Academy of Dermatology, 2021, 84, 1162-1164.	0.6	7
3	Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma. Oncotarget, 2021, 12, 2531-2540.	0.8	5
4	Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial. Clinical, Cosmetic and Investigational Dermatology, 2020, Volume 13, 117-121.	0.8	14
5	Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma. Oncotarget, 2020, 11, 3473-3483.	0.8	2
6	Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treatment Reviews, 2018, 64, 1-10.	3.4	63
7	Photodynamic therapy corrects abnormal cancer-associated gene expression observed in actinic keratosis lesions and induces a remodeling effect in photodamaged skin. Journal of Dermatological Science, 2018, 91, 206-218.	1.0	10
8	Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases. Plastic and Reconstructive Surgery - Global Open, 2017, 5, e1424.	0.3	36
9	Photodynamic Therapy and Non-Melanoma Skin Cancer. Cancers, 2016, 8, 98.	1.7	63
10	Defining locally advanced basal cell carcinoma and integrating smoothed inhibitors into clinical practice. Current Opinion in Oncology, 2016, 28, 180-184.	1.1	11
11	The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma. Expert Review of Anticancer Therapy, 2016, 16, 1011-1018.	1.1	9
12	The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. Journal of the American Academy of Dermatology, 2016, 75, 113-125.e5.	0.6	133
13	Non-melanoma skin cancer. Clinical Medicine, 2016, 16, 62-65.	0.8	66
14	Common variants modify the age of onset for basal cell carcinomas in Gorlin syndrome. European Journal of Human Genetics, 2015, 23, 708-710.	1.4	10
15	Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncology, The, 2015, 16, 716-728.	5.1	325
16	Mitigating the risk of skin cancer associated with thiopurine use. British Journal of Hospital Medicine (London, England: 2005), 2014, 75, 55-55.	0.2	0
17	Ingenol mebutate: a novel treatment for actinic keratosis. Clinical Practice (London, England), 2014, 11, 295-306.	0.1	8
18	Evidence for field cancerisation treatment of actinic keratoses with topical diclofenac in hyaluronic acid. European Journal of Dermatology, 2014, 24, 158-167.	0.3	21

#	ARTICLE	IF	CITATIONS
19	Evidence-based treatment for low-risk basal cell carcinoma. <i>Lancet Oncology</i> , The, 2014, 15, 12-13.	5.1	6
20	Sequential Treatment of Multiple Actinic Keratoses with Solaraze and Actikerall. <i>Case Reports in Dermatology</i> , 2014, 6, 164-168.	0.3	5
21	Increasing Capacity for Skin Surveillance in a Transplant Review Clinic. <i>Transplantation</i> , 2014, 97, e48-e50.	0.5	7
22	Use of Photodynamic Therapy for Treatment of Actinic Keratoses in Organ Transplant Recipients. <i>BioMed Research International</i> , 2013, 2013, 1-7.	0.9	22
23	Melanoma in Organ Transplant Recipients: Incidence, Outcomes and Management Considerations. <i>Journal of Skin Cancer</i> , 2012, 2012, 1-5.	0.5	10
24	Oral Hedgehog-Pathway Inhibitors for Basal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2012, 366, 2225-2226.	13.9	41
25	The Role of Ingenol Mebutate in the Treatment of Actinic Keratoses. <i>Dermatology and Therapy</i> , 2012, 2, 8.	1.4	17
26	Management of high-risk squamous cell carcinoma of the skin. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 763-769.	1.1	42
27	Focus on Basal Cell Carcinoma. <i>Journal of Skin Cancer</i> , 2011, 2011, 1-5.	0.5	27
28	Non-melanoma skin cancer. <i>Lancet</i> , The, 2010, 375, 673-685.	6.3	716
29	Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 247-251.	0.6	19
30	Clinical and Immunologic Results of a Phase II Trial of Sequential Imiquimod and Photodynamic Therapy for Vulval Intraepithelial Neoplasia. <i>Clinical Cancer Research</i> , 2008, 14, 5292-5299.	3.2	89
31	Photodynamic Therapy With Methyl Aminolevulinate for Prevention of New Skin Lesions in Transplant Recipients: A Randomized Study. <i>Transplantation</i> , 2008, 86, 423-429.	0.5	94
32	Pathergy. <i>Cmaj</i> , 2007, 176, 1275-1276.	0.9	0
33	Nonsurgical treatment options for nonmelanoma skin cancers. <i>Expert Review of Dermatology</i> , 2007, 2, 59-67.	0.3	2
34	Nodular basal cell carcinoma in Gorlin's syndrome treated with systemic photodynamic therapy and interstitial optical fiber diffuser laser. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, S86-S89.	0.6	18
35	Skin Cancer: Basal cell carcinoma: genetic homogeneity in a tumour type displaying phenotypic diversity. <i>European Journal of Human Genetics</i> , 2006, 14, 977-978.	1.4	2
36	Polymorphism in the nuclear excision repair gene ERCC2/XPD: association between an exon 6-exon 10 haplotype and susceptibility to cutaneous basal cell carcinoma. <i>Human Mutation</i> , 2005, 25, 353-359.	1.1	42

#	ARTICLE	IF	CITATIONS
37	Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 468-473.	0.6	73
38	PTCH polymorphism is associated with the rate of increase in basal cell carcinoma numbers during follow-up: Preliminary data on the influence of an exon 12-exon 23 haplotype. <i>Environmental and Molecular Mutagenesis</i> , 2004, 44, 469-476.	0.9	14
39	Associations between UVR exposure and basal cell carcinoma site and histology. <i>Cancer Letters</i> , 2004, 216, 191-197.	3.2	19
40	Combined effects of gender, skin type and polymorphic genes on clinical phenotype: use of rate of increase in numbers of basal cell carcinomas as a model system. <i>Cancer Letters</i> , 2003, 189, 175-181.	3.2	41
41	The rate of increase in the numbers of primary sporadic basal cell carcinomas during follow up is associated with age at first presentation. <i>Carcinogenesis</i> , 2002, 23, 2051-2054.	1.3	11
42	Association between functional polymorphism in EGF gene and malignant melanoma. <i>Lancet, The</i> , 2002, 359, 397-401.	6.3	244
43	Basal cell carcinomas: association of allelic variants with a high-risk subgroup of patients with the multiple presentation phenotype. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 247-254.	5.7	39
44	Susceptibility and modifier genes in cutaneous basal cell carcinomas and their associations with clinical phenotype. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2001, 63, 1-7.	1.7	13
45	Cutaneous basal cell carcinomas. <i>Cancer</i> , 2001, 92, 354-358.	2.0	66
46	Glutathione S-transferase GSTP1 and cyclin D1 genotypes: association with numbers of basal cell carcinomas in a patient subgroup at high-risk of multiple tumours. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 545-556.	5.7	35
47	Basal cell carcinoma. <i>Cancer</i> , 2000, 89, 1012-1018.	2.0	40
48	The melanocyte stimulating hormone receptor polymorphism: association of the V92M and A294H alleles with basal cell carcinoma. <i>Clinica Chimica Acta</i> , 1999, 282, 125-134.	0.5	23
49	Cytochrome P450 CYP2D6 genotypes. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 269-276.	5.7	37
50	Contact sensitivity and systemic reaction to pseudoephedrine and lignocaine. <i>Contact Dermatitis</i> , 1998, 39, 33-33.	0.8	13
51	Contact sensitivity in patients with oral symptoms. <i>Contact Dermatitis</i> , 1998, 39, 258-259.	0.8	15
52	Glutathione S-transferase polymorphisms: influence on susceptibility to cancer. <i>Chemico-Biological Interactions</i> , 1998, 111-112, 351-364.	1.7	63
53	Susceptibility to Melanoma: Influence of Skin Type and Polymorphism in the Melanocyte Stimulating Hormone Receptor Gene. <i>Journal of Investigative Dermatology</i> , 1998, 111, 218-221.	0.3	60
54	Azathioprine. <i>BioDrugs</i> , 1998, 9, 33-47.	2.2	42

#	ARTICLE	IF	CITATIONS
55	Patients With Truncal Basal Cell Carcinoma Represent a High-Risk Group. Archives of Dermatology, 1998, 134, 373.	1.7	13
56	Truncal Tumor Site Is Associated with high Risk of Multiple Basal Cell Carcinoma and Is Influenced by Glutathione S-Transferase, GSTT1, and Cytochrome P450, CYP1A1 Genotypes, and Their Interaction. Journal of Investigative Dermatology, 1997, 108, 519-522.	0.3	56
57	Retrospective review of the use of azathioprine in severe atopic dermatitis. Journal of the American Academy of Dermatology, 1996, 35, 642-643.	0.6	44
58	Multiple cutaneous basal cell carcinomas: glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual. Carcinogenesis, 1996, 17, 1891-1896.	1.3	110
59	Tests to assist in the diagnosis of keratinocyte skin cancers in adults: a generic protocol. The Cochrane Library, 0, , .	1.5	13